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Rapid diagnosticsStreptococcus pneumoniae (pneumococcus) is the most common bacterial etiology of community-acquired
pneumonia (CAP) in adults, a leading cause of death. Themajority of pneumococcal CAP is diagnosed by blood
culture, which likely underestimates the burden of disease. The 2007 CAP guidelines recommend routine use
of the rapid pneumococcal urinary antigen (UAg) test. To assess the how pneumococcal UAg testing is being
used among hospitalized adult CAP patients and what barriers restrict its use, a Web-based survey was
distributed in 2013 to 1287 infectious disease physician members of the Emerging Infectious disease Network
of the Infectious Disease Society of America. Of 493 eligible responses, 65% use the pneumococcal UAg test.
The primary barrier to UAg use was availability (46%). UAg users reported ordering fewer other diagnostic
tests and tailoring antibiotic therapy. Increased access to UAg tests could improve pneumonia management
and pneumococcal CAP surveillance.+1-404-638-5617.Published by Elsevier Inc.1. Introduction
Streptococcus pneumoniae (pneumococcus) is the most common
bacterial etiology of community-acquired pneumonia (CAP) in adults
(Klugman et al., 2008), a leading cause of morbidity and mortality in
the United States (Kung et al., 2008). In recent years, the incidence of
invasive pneumococcal disease, including bacteremic pneumococcal
pneumonia in adults, has been declining as a result of routine
vaccination of children with pneumococcal conjugate vaccines
(Pilishvili et al., 2010). The majority of pneumococcal pneumonia
cases are diagnosed by blood culture. However, because only about
25% of pneumococcal pneumonia cases are associated with bacteremia,
cliniciansmiss opportunities for apathogen-speciﬁc CAPdiagnosis (Said
et al., 2013). In addition, the burden of pneumococcal disease and
impact of pneumococcal conjugate vaccine are likely underestimated
(Said et al., 2013). Culture-independent diagnostic tests could improve
clinical care and non-invasive pneumococcal disease surveillance.
The pneumococcal urinary antigen (UAg) test was licensed by the
Food and Drug Administration in 1999 and has a reported sensitivity
of 50–80% and a speciﬁcity of N90% (Mandell et al., 2007). The 2007
IDSA/ATS guidelines for the management of CAP recommend the
routine use of the pneumococcal UAg test as an adjunct to blood
cultures for hospitalized patients with severe CAP (Mandell et al.,
2007). However, physicians do not always follow clinical practiceguidelines (Cabana et al., 1999). To understand how the pneumococ-
cal UAg test is being used in clinical practice and what barriers restrict
its use, we performed a Web-based survey of practicing infectious
disease (ID) physicians regarding their use of the pneumococcal UAg
test among hospitalized adult patients with CAP.2. Materials and methods
We surveyed ID physician members of the Infectious Diseases
Society of America (IDSA), Emerging Infections Network (EIN). The
EIN is a provider-based emerging infections sentinel network funded
by the Centers for Disease Control and Prevention to gather
information about clinical aspects of infectious diseases (Pillai et al.,
2014). An 11-question survey was distributed via e-mail or
facsimile to 1287 EIN members who care for adult patients from the
United States, Puerto Rico, and Canada in May 2013. Two reminders
were sent to non-responders over 3 weeks.
The physicians were asked how frequently they use the pneumo-
coccal UAg test and reasons why they do or do not use the test. We
also inquired about the clinical setting in which the test is used and
how results of the pneumococcal UAg test inﬂuence clinical decision
making. For comparison, the survey also asked about use of blood
cultures in CAP patients. Only respondents who reported that they
care for adult hospitalized CAP patients were included in the analysis.
A descriptive analysis was performed on completed questions;
denominators for certain questions varied, as not all physicians
responded to all questions. Comparisons between groups were made
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of b0.05 were considered statistically signiﬁcant.
3. Results
There were 592 (46%) respondents, consistent with other EIN
surveys (Gundlapalli et al., 2013). Characteristics of respondents,
including patient population, practice setting, and state of residence,
did not differ signiﬁcantly from those of non-respondents. However,
respondents were signiﬁcantly more likely than non-respondents to
have at least 15 years of clinical ID experience (P b 0.001). Ninety-
nine responses were excluded because the physicians reported that
they did not treat hospitalized adult patients with CAP, leaving a ﬁnal
sample of 493.
Of these respondents, 319 (65%) use the pneumococcal UAg test,
and 485 (98%) use blood cultures in clinical practice. Of the physicians
who use the pneumococcal UAg test, 71% had access to the test in their
clinical lab, and 29% order it as a send-out to another laboratory.
Respondents who do not use the UAg test (N = 174, 35%) provided
several reasons for not doing so, including lack of availability (46%),
results not available in a timely fashion (33%), a belief that results
would not inﬂuence clinical decision making (32%), perceived poor
reliability (12%), high cost (9%), and inability to obtain susceptibility
results (7%).
We observed wide geographic variations in use of the pneumo-
coccal UAg test (Table 1), with highest use in southern regions (range
74–84%) and lower use among northern and western regions of the
country (range 48–68%). There were no signiﬁcant differences in UAg
usage with years of experience since completing ID training. There
was a non-signiﬁcant (P = 0.06) trend toward differences in UAg
usage with community (74%) and Veterans Affairs/Department of
Defense (72%) hospitals using the UAg test more than teaching (60%)
and city or county hospitals (60%).
Because blood cultures have been a routine diagnostic method
among CAP patients for many years, we compared the frequency of
UAg testing to blood culture. Among those who do use blood cultures
or UAg, blood cultures are used more commonly among all patients
with CAP, whereas UAg testing tends to be used only in selected CAP
patients (Table 2).Table 1
Reported usage and availability of the pneumococcal UAg test by region, clinical experience
Total responded,
N = 493 (38%)
UAg usage,
N = 319 (65%)
Region, N (%)
East South Central 19 (33) 16 (84)
South Atlantic 75 (33) 62 (83)
West South Central 34 (40) 25 (74)
East North Central 76 (40) 52 (68)
Mountain 34 (47) 23 (68)
New England 40 (43) 26 (65)
West North Central 50 (40) 31 (62)
Mid Atlantic 76 (39) 44 (58)
Paciﬁc 80 (36) 38 (48)
Canada 8 (38) 2 (25)
Years since ID fellowship, N (%)
b5 117 (38) 81 (69)
5–14 112 (29) 75 (67)
15–24 129 (43) 74 (57)
≥25 134 (47) 89 (66)
Primary hospital type, N (%)
Community 147 (38) 109 (74)
VA/DOD hospital 32 (39) 23 (72)
Non-university teaching 143 (40) 88 (62)
City/county hospital 20 (53) 12 (60)
University 149 (36) 86 (57)
Other 2 (14) 1 (50)
VA = Veterans Affairs; DOD = Department of Defense.The UAg is recommended to be used for inpatient settings so we
asked physicians about the clinical settings in which they use UAg and
blood cultures. Of those respondents who use these tests, over 93% of
respondents order blood cultures, and over 87% of respondents order
the UAg test for inpatients with CAP. Even greater (P b 0.001)
proportions of respondents indicated use of these tests for intensive
care unit (ICU) patients (Table 2).
Over 80% of respondents who use UAg reported that results
inﬂuenced clinical decision making (Table 2). The most common
changes in clinical management related to the ordering of fewer other
diagnostic tests, narrowing of antibiotic regimens, and shortening of
antibiotic courses for positive UAg results.
Since ID physicians usually see CAP patients after initial evaluation
and management, we inquired about respondent's perception of non-
ID physicians' use of blood cultures and UAg (Table 2). Non-ID
physicians were perceived to use the UAg test some of the time for
CAP patients (48%) and blood cultures most of the time or always
(69%). Few non-ID physicians were perceived to use the UAg always
(3%) or most of the time (17%).
4. Discussion
ID diagnostics are shifting from the traditional culture-based
methods to culture-independent methods such as the pneumococcal
UAg test. Our survey indicates that 65% of ID physicians use the
pneumococcal UAg test routinely; however, they report that b20% of
non-ID physicians were perceived to use UAg testing most of the time
or always. Importantly, ID physicians alter clinical management in
response to a positive UAg test in ways similar to a positive blood
culture for S. pneumoniae.
Improved CAP diagnostic yield may lead to better clinical practice.
The recommended empiric CAP treatment for inpatients is broad,
including either a ﬂuoroquinolone or a third-generation cephalospo-
rin plus a macrolide, to cover many possible pneumonia-causing
organisms (Bartlett, 2011). Data support use of β-lactams in adult CAP
patients with a positive UAg test (Guchev et al., 2005; Stralin et al.,
2005), and results from our survey indicate that the majority of ID
physicians who use the UAg test narrow therapy in response to a
positive test. The main reasons physicians reported for not using the, and hospital type.
UAg available in clinical lab,
N = 217 (68%)
UAg available as send-out test,
N = 87 (27%)
12 (75) 3 (19)
38 (61) 23 (37)
15 (60) 9 (36)
43 (83) 8 (15)
18 (78) 5 (22)
18 (69) 7 (27)
23 (74) 6 (19)
33 (75) 5 (11)
16 (42) 22 (58)
1 (50) 1 (50)
55 (68) 21 (26)
50 (67) 21 (28)
49 (66) 22 (30)
63 (71) 23 (26)
75 (69) 28 (26)
13 (57) 9 (39)
66 (75) 19 (22)
5 (42) 6 (50)
57 (66) 25 (29)
1 (100) 0 (0)
Table 2
Use of blood culture and pneumococcal UAg test for adult patients with CAP.
Blood culture (%) UAg test (%) P-value
Do you order blood cultures or the pneumococcal UAg test for patients with CAP in your clinical practice?
Yes 485 (98) 319 (65) b0.001
Of those who use the test, where is the test used?a
Outpatient 75 (16) 48 (15) 0.918
Inpatient, non-ICU 445 (93) 271 (87) 0.005
Inpatient, ICU 469 (98) 299 (96) 0.089
Other 17 (4) 13 (4) 0.657
Of those who use the test, which patients are tested?a
All CAP patients 306 (64) 133 (42) b0.001
The majority of CAP patients 133 (28) 109 (35) 0.034
Only certain CAP patients, i.e., ICU 41 (9) 64 (20) b0.001
Other 1 (b1) 8 (3) 0.002
How do results inﬂuence clinical management for a positive result?b
Narrow antibiotic regimen 433 (90) 262 (84) 0.012
Shorten antibiotic course 117 (24) 88 (28) 0.219
Order fewer diagnostic tests 304 (63) 209 (67) 0.266
No change in clinical management 7 (1) 10 (3) 0.096
Other 32 (7) 6 (2) 0.002
How often do non-ID clinicians use these tests for patients with CAP?c
Always 65 (13) 12 (3) b0.001
Most of the time 275 (56) 76 (17) b0.001
Some of the time 142 (29) 213 (48) b0.001
Not at all 6 (1) 125 (28) b0.001
Not sure 1 (b1) 14 (3) b0.001
a Responses varied for blood culture (N = 479) and UAg (N = 312).
b Responses varied for blood culture (N = 480) and UAg (N = 311).
c Responses varied for blood culture (N = 489) and UAg (N = 440).
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settings or lack of timeliness as the test is often sent out for analysis.
For send-out testing, the delay in result reporting could be up to a
week, which may be too late to alter treatment. Therefore, healthcare
centers could improve the quality of care for adult CAP patients with
pathogen-directed therapy by making this test more available.
Respondents listed potential reasons in the free-text comments of
the survey for why UAg is not available in their clinical setting and
included: cost, extra training due to the Clinical Laboratory Improve-
ment Amendments (CLIA), and shelf life of the UAg kit. Regarding
cost, the UAg test is estimated to cost between $30 and 40 per test in
the United States. An algorithm to determine cost savings of UAg in
Europe 2003 showed that patients started empirically on narrow
spectrum (less expensive therapy) and used UAg had cost savings of ~
$9.16 compared to those started empirically on broad spectrum
(expensive therapy), which had cost excess of ~$27.41 (Oosterheert
et al., 2003). However, it is unclear from this study how cost savings
would be impacted if patients started on empiric therapy subse-
quently had therapy tailored toward pneumococcus after a positive
test. Unfortunately, while UAg testing is rapid and easy to use, CLIA
restricts use to trained technicians in a CLIA-certiﬁed laboratory.
Lastly, the shelf life of the UAg kit is at least 2 years. We suggest that
the UAg test could be integrated into electronic medical order sets to
increase clinical use and results of this survey be considered in future
CAP clinical guidelines to routinely recommend UAg testing for all
CAP patients.
Current pneumococcal surveillance depends on culture-based
methods (Williams et al., 2011). Non-bacteremic pneumococcal
pneumonia is often not diagnosed with culture-based methods.
Therefore, the burden of non-bacteremic pneumococcal pneumonia
is difﬁcult to estimate but is clearly larger than the burden of
bacteremic pneumococcal pneumonia (Said et al., 2013). Culture-
independent tests, such as the pneumococcal UAg test, may be an
important tool to incorporate into surveillance systems to better
estimate the burden of pneumococcal pneumonia.
Results of the survey should be interpreted with consideration of
important limitations. The 46% of individuals who responded to our
survey may not be representative of those who did not respond. TheEIN is limited to ID physicians who belong to IDSA and is not
representative of all physicians. Non-ID clinicians are usually the ﬁrst
to start the evaluation of hospitalized CAP patients and were not
surveyed directly. In addition, respondents' reported use of the UAg
test may differ from their actual practice.
Inappropriate antibiotic use with cephalosporins and macrolides
has contributed to emerging antibiotic resistance for pneumococci
(Hicks et al., 2011); thus, pathogen-speciﬁc CAP diagnosis remains
critical. While a positive UAg test does not provide susceptibility
results, it can reassure clinicians that other pathogens (e.g., Staphylococcus
aureus) requiring broader-spectrum therapy are less likely to be playing a
role in a particular patient's illness. Our survey suggests that physicians
with access to the test are using rapid culture-independent diagnostics for
hospitalized adult CAP patients more frequently. We suggest that use of
the UAg test would improve quality of care by allowing clinicians to use
more targeted therapy and may be incorporated into population-based
surveillance systems to better estimate the burden of non-bacteremic
pneumococcal CAP.Acknowledgments
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